KOSDAQBiotech & Pharma142280

GC Medical Science

₩2,755▼ 0.54%2026-11-18 close
Market Cap
₩66B
Turnover
₩200M
Volume
70K
Shares out.
24M
PER
—
PBR
1.2×
EPS
-₩226
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit rising, net losses remain the test

GC Medical Science has grown operating profit for two straight years since its 2023 turn to profit, but net losses attributable to controlling shareholders have continued since the second quarter of 2026, making net earnings the next checkpoint.

  1. 1

    Operating profit moved from an operating loss of KRW 1.26 billion in 2022 to KRW 2.89 billion in 2025, with the operating margin at 2.7% in 2025.

  2. 2

    Third-quarter 2026 operating profit of KRW 1.14 billion rose 20.5% from a year earlier, while net loss attributable to controlling shareholders in the same quarter was KRW 1.52 billion.

  3. 3

    Net losses attributable to controlling shareholders over the last four quarters total KRW 5.04 billion, and the second and third quarters of 2026 were both loss-making.

  4. 4

    The debt ratio fell from 170.6% in 2022 to 95.2% in 2025, and total equity stood at KRW 46.4 billion at the end of 2025.

  5. 5

    On the business side, the company received Ministry of Food and Drug Safety export approvals for two hantavirus diagnostic kits on October 30 and November 12, 2026.

02

Business structure

GC Medical Science was founded in 2003 as a maker of in-vitro diagnostic reagents and medical devices, and diagnostic reagents and blood glucose meters form the core of the business.

It entered blood glucose testing in 2015 through its acquisition of GC Medimedis and now sells immunodiagnostic, biochemical and molecular diagnostic reagents along with glucose meters, HbA1c analyzers and lipid analyzers.

The company also runs a hemodialysis solution business and expanded its hemodialysis solution plant to meet rising demand. Through portfolio streamlining it sold off its blood bag business.

In infectious disease diagnostics, it holds export approvals for six reagents covering dengue (four), chikungunya (one) and mpox (one), plus one domestic malaria reagent, and in 2026 it added hantavirus rapid and PCR-based molecular kits.

Sales run mainly through its existing overseas sales network, and the company plans to expand the countries and products it serves. GC Biopharma is the largest shareholder with a 40.3% stake, according to a May 2025 securities firm report.

The company has also agreed a strategic partnership with China-based Yuwell to bring continuous glucose monitors into Korea, with GC Medical Science handling domestic approvals, marketing and distribution, and Yuwell handling manufacturing and technical and regulatory documentation.

Competition is most naturally compared on diagnostic test menus, overseas approval scope and the glucose product lineup.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩26.4B₩900M3.6%
2025Q4₩25B₩400M1.6%
2026Q1₩23.6B₩300M1.2%
2026Q2₩27.1B₩700M2.7%
2026Q3₩27B₩1.1B4.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩113.1B-₩1.3B-₩3.6B−1.1%−10.8%170.6%
2023₩94B₩1.8B₩1.8B1.9%5.2%145.2%
2024₩103.9B₩2.3B₩3.6B2.2%8.7%102.6%
2025₩108.4B₩2.9B₩3.7B2.7%8.3%95.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On an annual basis, revenue was largest in 2022 at KRW 113.1 billion and smallest in 2023 at KRW 94 billion, a 16.9% decline from the prior year. Revenue then rose 10.5% to KRW 103.9 billion in 2024 and 4.4% to KRW 108.4 billion in 2025, growing two years in a row from 2024 through 2025.

Operating profit swung from an operating loss of KRW 1.26 billion in 2022 to operating profit of KRW 1.8 billion in 2023, a turn to profit, before rising 29.7% to KRW 2.33 billion in 2024 and 23.7% to KRW 2.89 billion in 2025.

The operating margin improved from -1.1% in 2022 to 2.7% in 2025, and the return to profit in 2023, a year of falling revenue, marks the start of that shift.

Net profit attributable to controlling shareholders went from a net loss of KRW 3.58 billion in 2022 to KRW 1.8 billion in 2023, then rose 99.2% to KRW 3.58 billion in 2024 and 2.4% to KRW 3.67 billion in 2025.

Net profit including non-controlling interests was KRW 3.46 billion in 2025, a different figure from the controlling-shareholder number. Operating cash flow fell from KRW 10.9 billion in 2022 to KRW 4.24 billion in 2023 and KRW 3.66 billion in 2024, then recovered to KRW 7.2 billion in 2025.

Quarterly revenue slid from KRW 26.4 billion in the third quarter of 2025 to KRW 25 billion in the fourth quarter and KRW 23.6 billion in the first quarter of 2026, then rebounded to KRW 27.1 billion in the second quarter (up 15.1% quarter on quarter) and KRW 27 billion in the third quarter.

Operating profit bottomed at KRW 292 million in the first quarter of 2026 and then rose to KRW 743 million in the second quarter and KRW 1.14 billion in the third quarter, two straight quarters of growth.

Net profit attributable to controlling shareholders, by contrast, moved from KRW 1.36 billion in the third quarter of 2025 to a net loss of KRW 4.03 billion in the second quarter of 2026, a swing into loss, and narrowed to a net loss of KRW 1.52 billion in the third quarter.

The company's preliminary disclosure said the third-quarter non-operating result included a non-cash valuation gain or loss from the partial conversion of its fifth bond with warrants into common shares.

Operating gains have not yet carried through to the net line, so non-operating items are the variable to watch in the next quarters.

05

Industry analysis

Diagnostic reagent sales tend to swing quarter to quarter with infectious disease outbreaks and overseas testing demand. A May 2025 securities firm report said the company was working through inventory-related losses left from the pandemic and shifting back to profitable operations.

Read as a cycle position, that suggests a phase of rebuilding the earnings base after inventory adjustment. The same report noted that infectious disease diagnostic sales could grow, centered on the Middle East, Africa and West Asia.

The company has widened its product format by adding rapid and molecular kits to its ELISA-based research reagents. In blood glucose testing it is pushing to bring continuous glucose monitors into Korea, extending its glucose management lineup.

Diagnostic products are most naturally compared on test menu breadth and overseas approval scope, while glucose products are compared on measurement method and speed of regulatory approval.

Against larger listed companies in the same biopharma sector, its revenue base is smaller and its weighting toward diagnostics and medical devices is higher. On the strength side, rising demand for infectious disease testing stands out, while demand volatility and pricing pressure are the main weaknesses.

06

Outlook

On November 18, 2026, the company announced that it had received Ministry of Food and Drug Safety export approvals for a rapid hantavirus diagnostic kit on October 30 and a PCR-based molecular hantavirus kit on November 12.

The company plans to expand the countries and products it sells into through its existing overseas sales network. It has also stated that it will keep developing and commercializing diagnostic products for major infectious diseases, including mpox and Ebola.

The planned domestic launch of continuous glucose monitors is structured so that GC Medical Science handles domestic approvals, marketing and distribution. How quickly these export approvals turn into reported revenue, and at what scale, has to be confirmed in upcoming quarterly results.

Whether the non-cash valuation items booked in non-operating income in the third quarter of 2026 recur in later quarters is a variable for the net earnings trend. The 2026 annual business report, the next regular filing, will show whether the full-year operating margin moves above the 2.7% recorded in 2025.

Since operating profit has risen quarter on quarter through the third quarter of 2026, whether the fourth quarter holds near the KRW 1.14 billion level is also worth tracking. The main open question is whether net profit attributable to controlling shareholders can follow operating profit back into the black.

07

Valuation

PER
—
PBR
1.2×
ROE
-10.3%
EPS
-₩226
BPS
₩2,372
Dividend per share
₩0

Net losses attributable to controlling shareholders over the last four quarters total KRW 5.04 billion, so a price-to-earnings ratio cannot be calculated on that basis.

The price-to-book ratio sits slightly above 1x, which means the stock trades at a modest premium to net asset value measured against the controlling-shareholder equity of KRW 44.4 billion at the end of 2025. The dividend yield is close to zero, so the shareholder return signal from dividends is weak.

To read the price against net assets, the key variable is how quickly the company builds profit on its equity base. Over several years the direction is clear: a controlling-shareholder net loss in 2022 turned to profit in 2023 and reached KRW 3.67 billion in 2025.

Continuity of that recovery has yet to be confirmed quarter by quarter, given the net loss swing after the second quarter of 2026. Valuation reading here is best organized around the link between the share price and net assets, together with the profit trend excluding non-cash non-operating items.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Operating-level improvement

The operating margin rose from -1.1% in 2022 to 2.7% in 2025, and operating profit grew to KRW 2.89 billion in 2025 after growing in 2024. It reached KRW 743 million in the second quarter of 2026 and KRW 1.14 billion in the third, two straight quarters of growth, with the third quarter up 20.5% from a year earlier. The continuation of profitable operations at the operating level is the core bullish point.

Wider infectious disease export lineup

Export approvals for a rapid kit on October 30 and a PCR molecular kit on November 12, 2026 added hantavirus products to the existing export reagent range. Adding rapid and molecular formats to ELISA-based research reagents broadens the testing methods the company can offer. The plan is to use the existing overseas sales network to expand the countries and products sold.

Balance sheet repair and profit continuity

The debt ratio fell from 170.6% in 2022 to 95.2% in 2025, with total liabilities at KRW 44.1 billion and total equity at KRW 46.4 billion at the end of 2025. After turning to profit in 2023, net profit attributable to controlling shareholders grew in 2024 and 2025. The lighter debt load alongside accumulating earnings is the supporting factor on the bull side.

09

Bear factors

Persistent net losses for controlling shareholders

Net loss attributable to controlling shareholders was KRW 4.03 billion in the second quarter of 2026 and KRW 1.52 billion in the third, two straight loss-making quarters. The four-quarter total stands at KRW 5.04 billion.

Because net results stayed negative even as operating profit rose, the influence of non-operating items looms large.

No clear quarterly revenue growth

Quarterly revenue fell from KRW 26.4 billion in the third quarter of 2025 to KRW 25 billion in the fourth quarter and KRW 23.6 billion in the first quarter of 2026. The third quarter of 2026 at KRW 27 billion was only 2.3% above the year-earlier quarter.

Since the third quarter of 2025, quarterly revenue has moved between KRW 23.6 billion and KRW 27.1 billion, with no clear growth trend.

Limited cash flow recovery

Operating cash flow fell from KRW 10.9 billion in 2022 to KRW 3.66 billion in 2024. It recovered to KRW 7.2 billion in 2025 but remains below the 2022 level. Cash generation has not kept pace with the earnings improvement, which is the main bearish point.

10

Risk factors

Non-operating and non-cash items

Non-cash valuation gains and losses tied to the conversion of bonds with warrants into common shares can swing quarterly net results. The company said such items were reflected in third-quarter non-operating income. The gap between operating profit and net profit may widen from quarter to quarter.

Export approvals and domestic licensing

Infectious disease diagnostic exports depend on country-by-country approvals and on whether outbreaks occur. Bringing continuous glucose monitors into Korea requires prior approval from the Ministry of Food and Drug Safety, and no timing has been set. If approval timelines slip, the revenue effect of the wider product range could also be delayed.

Shareholder structure and group ties

GC Biopharma is the largest shareholder with a 40.3% stake, according to a May 2025 securities firm report. Changes to the shareholder structure or the terms of intragroup transactions could matter for minority holders. How the overseas sales network is shared within the group could also change how the earnings are read.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    Confirm the audited 2026 full-year revenue, operating profit and net profit attributable to controlling shareholders. The key is how fourth-quarter results and non-operating items flowed into the annual net figure.

  2. Late April to early May 2027 (expected timing of Q1 results)

    Compare first-quarter 2027 operating profit with KRW 292 million in the first quarter of 2026. Also check whether net profit attributable to controlling shareholders returned to the black and whether revenue from the newly approved export kits appears.

  3. During 2027 (timing not set)

    Track the domestic approval progress and launch schedule for the continuous glucose monitors being brought in with Yuwell. The checkpoint is whether the expanded glucose lineup shows up as actual revenue.

12

Overall view

GC Medical Science has grown operating profit each year since its 2023 turn to profit, through 2025, and its debt ratio fell from 170.6% in 2022 to 95.2% in 2025. Third-quarter 2026 operating profit of KRW 1.14 billion was up 20.5% from a year earlier.

Net results tell a different story: net losses attributable to controlling shareholders were KRW 4.03 billion in the second quarter of 2026 and KRW 1.52 billion in the third, two straight loss quarters, with a four-quarter total of KRW 5.04 billion.

The company attributed part of the third-quarter net swing to non-cash valuation items in non-operating income. Quarterly revenue has moved between KRW 23.6 billion and KRW 27.1 billion since the third quarter of 2025, and a clear growth trend has not yet appeared.

Expanded infectious disease export approvals and the planned launch of continuous glucose monitors are the business expansion factors. The next checkpoints are the audited 2026 results in the annual report and first-quarter 2027 results, and the central question is whether net profit follows the operating improvement.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. digitaltoday.co.kr
  3. saramin.co.kr
  4. samsungpop.com
  5. greencrossms.com
  6. thefairnews.co.kr
  7. fntimes.com
  8. m.sedaily.com
  9. ggilbo.com
  10. vegannews.co.kr
  11. dailymagazine.co.kr
  12. etoday.co.kr
  13. s-journal.co.kr
  14. newspost.kr
  15. 100ssd.co.kr
  16. news1.kr
  17. news.nate.com
  18. fnnews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis